Search

A novel numerical methodology is used to investigate the behavior of an all-composite wing-box under a compressive load taking into account the presence of concurrent inter-laminar damages such as delaminations and skin-stringer debonds and their propagation. The proposed numerical methodology, based on linear structural analyses, is computationally inexpensive if compared to the VCCT and CZM based numerical techniques, hence, it appears to be particularly suitable for the preliminary design phase of complex structure. The presented linear approach is an evolution of a previous technique developed specifically for delaminations. Indeed, in this paper the linear approach has been enhanced to predict the propagation of inter-laminar damages with open crack surfaces such as skin-stringer debonds and it has been implemented in a commercial Finite Element platform. The effectiveness (in terms of computational cost and accuracy of results) of the suggested linear numerical methodology, in predicting the compressive behavior of complex composite structures with inter-laminar damages, has been confirmed by cross-comparisons with the standard non-linear VCCT technique. Finally, comparisons in terms of critical propagation load and Energy Release Rate distribution along the damage tip predictions, for several examined structural configurations with different damage extension and depth, have allowed to assess the field of applicability of the propose novel numerical methodology. [ABSTRACT FROM AUTHOR]

In this work a numerical study on the impact behavior of an all composite wing-box is presented. The numerical analyses have been performed by means of advanced numerical models implemented in Abaqus/Explicit. The aim was to estimate the intra-laminar and inter-laminar damage behaviour in a localized area, and, by a Global-local approach, to investigate the impact influence on the overall structural behaviour. The numerical investigation of complex composite structures under several impact conditions in terms of impact position and energy can complement the experimental results potentially leading to a reduction of the experimental tests to be performed with considerable time and cost saving. [ABSTRACT FROM AUTHOR]

A blood-stage Plasmodium falciparum malaria vaccine would provide a second line of defence to complement partially effective or waning immunity conferred by the approved pre-erythrocytic vaccines. RH5.1 is a soluble protein vaccine candidate for blood-stage P falciparum , formulated with Matrix-M adjuvant to assess safety and immunogenicity in a malaria-endemic adult and paediatric population for the first time. We did a non-randomised, phase 1b, single-centre, dose-escalation, age de-escalation, first-in-human trial of RH5.1/Matrix-M in Bagamoyo, Tanzania. We recruited healthy adults (aged 18–45 years) and children (aged 5–17 months) to receive the RH5.1/Matrix-M vaccine candidate in the following three-dose regimens: 10 μg RH5.1 at 0, 1, and 2 months (Adults 10M), and the higher dose of 50 μg RH5.1 at 0 and 1 month and 10 μg RH5.1 at 6 months (delayed-fractional third dose regimen; Adults DFx). Children received either 10 μg RH5.1 at 0, 1, and 2 months (Children 10M) or 10 μg RH5.1 at 0, 1, and 6 months (delayed third dose regimen; Children 10D), and were recruited in parallel, followed by children who received the dose-escalation regimen (Children DFx) and children with higher malaria pre-exposure who also received the dose-escalation regimen (High Children DFx). All RH5.1 doses were formulated with 50 μg Matrix-M adjuvant. Primary outcomes for vaccine safety were solicited and unsolicited adverse events after each vaccination, along with any serious adverse events during the study period. The secondary outcome measures for immunogenicity were the concentration and avidity of anti-RH5.1 serum IgG antibodies and their percentage growth inhibition activity (GIA) in vitro, as well as cellular immunogenicity to RH5.1. All participants receiving at least one dose of vaccine were included in the primary analyses. This trial is registered at ClinicalTrials.gov , NCT04318002 , and is now complete. Between Jan 25, 2021, and April 15, 2021, we recruited 12 adults (six [50%] in the Adults 10M group and six [50%] in the Adults DFx group) and 48 children (12 each in the Children 10M, Children 10D, Children DFx, and High Children DFx groups). 57 (95%) of 60 participants completed the vaccination series and 55 (92%) completed 22 months of follow-up following the third vaccination. Vaccinations were well-tolerated across both age groups. There were five serious adverse events involving four child participants during the trial, none of which were deemed related to vaccination. RH5-specific T cell and serum IgG antibody responses were induced by vaccination and purified total IgG showed in vitro GIA against P falciparum. We found similar functional quality (ie, GIA per μg RH5-specific IgG) across all age groups and dosing regimens at 14 days after the final vaccination; the concentration of RH5.1-specific polyclonal IgG required to give 50% GIA was 14·3 μg/mL (95% CI 13·4–15·2). 11 children were vaccinated with the delayed third dose regimen and showed the highest median anti-RH5 serum IgG concentration 14 days following the third vaccination (723 μg/mL [IQR 511–1000]), resulting in all 11 who received the full series showing greater than 60% GIA following dilution of total IgG to 2·5 mg/mL (median 88% [IQR 81–94]). The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5–17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previously associated with protective outcome against blood-stage P falciparum challenge in non-human primates. These data support onward efficacy assessment of this vaccine candidate against clinical malaria in young African children. The European and Developing Countries Clinical Trials Partnership; the UK Medical Research Council; the UK Department for International Development; the National Institute for Health and Care Research Oxford Biomedical Research Centre; the Division of Intramural Research, National Institute of Allergy and Infectious Diseases; the US Agency for International Development; and the Wellcome Trust. [ABSTRACT FROM AUTHOR]

Abstract: Measurements of UV spectra, total ozone, cloud cover, and cloud optical thickness, obtained at Lampedusa (central Mediterranean), are used to investigate the influence of clouds on the spectral UV irradiance, through the cloud modification factor (CMF), and on five biological processes. The CMF decreases with cloud optical thickness (COT), from about 0.5 for COT∼15 to 0.25 for COT∼45, and decreases with increasing wavelength above 315–320-nm. Observations display an increase in the CMF from 295 to 320-nm, which is related to enhanced absorption by tropospheric ozone due to the long photon path lengths under cloudy conditions. The use of a wavelength independent CMF instead of the experimentally determined spectral curves produces an overestimation of the biological effects of UV irradiance. The overestimation may be as large as 30% for the DNA damage, 20% for vitamin D synthesis, 12% for plant damage, and 8–10% for phytoplankton inhibition and erythema. [Copyright &y& Elsevier]